Our aim should be to utilize the therapeutic benefits of the ACKR3/CXCR7 agonist as an anti-thrombotic agent without inflicting neoplastic changes, and while doing so, to substantiate a functional recovery of the afflicted organs (e.g., myocardium) following thrombo-inflammatory and thrombo-ischemic damage, as effectively demonstrated for myocardial infarction [27,28,76]. Here, ACKR3 is linked to myocardial infarction.